Dalila Alves

Dalila Alves

Auto-generated profile, based on publicly available information

Dalila Alves

Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Ophthalmology
Verified
Journal Article
Open access
JCJohanna M Colijn
Johanna M Colijn
GBGabriëlle H S Buitendijk
Gabriëlle H S Buitendijk
EPElena Prokofyeva
Elena Prokofyeva
DADalila Alves
Dalila Alves
MCMaria L Cachulo
Maria L Cachulo
ECEuropean Eye Epidemiology (E3) consortium
European Eye Epidemiology (E3) consortium
Age-related macular degeneration (AMD) is a frequent, complex disorder in elderly of European ancestry. Risk profiles and treatment options have changed considerably over the years, which may have affected disease prevalence and outcome. We determined the prevalence of early and late AMD in Europe from 1990 to 2013 using the European Eye Epidemiology (E3) consortium, and made projections for the future. Meta-analysis of prevalence data. A total of 42 080 individuals 40 years of age and older participating in 14 population-based cohorts from 10 countries in Europe. AMD was diagnosed based on fundus photographs using the Rotterdam Classification. Prevalence of early and late AMD was calculated using random-effects meta-analysis stratified for age, birth cohort, gender, geographic region, and time period of the study. Best-corrected visual acuity (BCVA) was compared between late AMD subtypes; geographic atrophy (GA) and choroidal neovascularization (CNV). Prevalence of early and late AMD, BCVA, and number of AMD cases. Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1%-5.0%) in those aged 55-59 years to 17.6% (95% CI 13.6%-21.5%) in those aged ≥85 years; for late AMD these figures were 0.1% (95% CI 0.04%-0.3%) and 9.8% (95% CI 6.3%-13.3%), respectively. We observed a decreasing prevalence of late AMD after 2006, which became most prominent after age 70. Prevalences were similar for gender across all age groups except for late AMD in the oldest age category, and a trend was found showing a higher prevalence of CNV in Northern Europe. After 2006, fewer eyes and fewer ≥80-year-old subjects with CNV were visually impaired (P = 0.016). Projections of AMD showed an almost doubling of affected persons despite a decreasing prevalence. By 2040, the number of individuals in Europe with early AMD will range between 14.9 and 21.5 million, and for late AMD between 3.9 and 4.8 million. We observed a decreasing prevalence of AMD and an improvement in visual acuity in CNV occuring over the past 2 decades in Europe. Healthier lifestyles and implementation of anti-vascular endothelial growth factor treatment are the most likely explanations. Nevertheless, the numbers of affected subjects will increase considerably in the next 2 decades. AMD continues to remain a significant public health problem among Europeans.

1 May 2018 in Ophthalmology
Verified
Journal Article
Closed access
JFJoao Figueira
Joao Figueira
EFEmily Fletcher
Emily Fletcher
PMPascale Massin
Pascale Massin
RSRufino Silva
Rufino Silva
Francesco BandelloFrancesco Bandello
Francesco Bandello
JCJosé Cunha-Vaz
José Cunha-Vaz

1 June 2018 in Retina
Verified
Journal Article
Closed access
PDF file
ASAna R. Santos
Ana R. Santos
MCMiguel Â. Costa
Miguel Â. Costa
CSChristian Schwartz
Christian Schwartz
DADalila Alves
Dalila Alves
JFJoão Figueira
João Figueira
JCJosé Cunha-Vaz
José Cunha-Vaz
Purpose: To identify baseline optical coherence tomography morphologic characteristics predicting the visual response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Methods: Sixty-seven patients with diabetic macular edema completed a prospective, observational study (NCT01947881-CHARTRES). All patients received monthly intravitreal injections of Lucentis for 3 months followed by PRN treatment and underwent best-corrected visual acuity measurements and spectral domain optical coherence tomography at Baseline, Months 1, 2, 3, and 6. Visual treatment response was characterized as good (≥10 letters), moderate (5–10 letters), and poor (<5 or letters loss). Spectral domain optical coherence tomography images were graded before and after treatment by a certified Reading Center. Results: One month after loading dose, 26 patients (38.80%) were identified as good responders, 19 (28.35%) as Moderate and 22 (32.83%) as poor responders. There were no significant best-corrected visual acuity and central retinal thickness differences at baseline (P = 0.176; P = 0.573, respectively). Ellipsoid zone disruption and disorganization of retinal inner layers were good predictors for treatment response, representing a significant risk for poor visual recovery to anti-vascular endothelial growth factor therapy (odds ratio = 10.96; P < 0.001 for ellipsoid zone disruption and odds ratio = 7.05; P = 0.034 for disorganization of retinal inner layers). Conclusion: Damage of ellipsoid zone, higher values of disorganization of retinal inner layers, and central retinal thickness decrease are good predictors of best-corrected visual acuity response to anti-vascular endothelial growth factor therapy.

1 July 2018 in Nutrition
Verified
Journal Article
Closed access
SNSandrina Nunes
Sandrina Nunes
DADalila Alves
Dalila Alves
PBPatrícia Barreto
Patrícia Barreto
MRMiguel Raimundo
Miguel Raimundo
MCMaria da Luz Cachulo
Maria da Luz Cachulo
RSRufino Silva
Rufino Silva

21 August 2015 in Ophthalmic Research
Verified
Journal Article
Closed access
PDF file
Francesco BandelloFrancesco Bandello
Francesco Bandello
Amparo NaveaAmparo Navea
Amparo Navea
SVStela Vujosevic
Stela Vujosevic
MVMonica Varano
Monica Varano
CECatherine Egan
Catherine Egan
FEFor The Evicr.NEt
For The Evicr.NEt
Purpose: To identify the retinal layer predominantly affected in eyes with subclinical and clinical macular edema in diabetes type 2. Methods: A cohort of 194 type 2 diabetic eyes/patients with mild nonproliferative diabetic retinopathy (ETDRS levels 20/35) were examined with Cirrus spectral-domain optical coherence tomography (OCT) at the baseline visit (ClinicalTrials.gov identifier: NCT01145599). Automated segmentation of the retinal layers of the eyes with subclinical and clinical macular edema was compared with a sample of 31 eyes from diabetic patients with normal OCT and an age-matched control group of 58 healthy eyes. Results: From the 194 eyes in the study, 62 had subclinical macular edema and 12 had clinical macular edema. The highest increases in retinal thickness (RT) were found in the inner nuclear layer (INL; 33.6% in subclinical macular edema and 81.8% in clinical macular edema). Increases were also found in the neighboring layers. Thinning of the retina was registered in the retinal nerve fiber, ganglion cells and inner plexiform layers in the diabetic eyes without macular edema. Conclusions: The increase in RT occurring in diabetic eyes with macular edema is predominantly located in the INL but extends to neighboring retinal layers indicating that it may be due to extracellular fluid accumulation.

14 September 2018 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
MRMiguel Raimundo
Miguel Raimundo
FMFilipe Mira
Filipe Mira
MCMaria da Luz Cachulo
Maria da Luz Cachulo
PBPatrícia Barreto
Patrícia Barreto
LRLuísa Ribeiro
Luísa Ribeiro
RSRufino Silva
Rufino Silva